Charles S. Berkman
2012 - Ligand Pharmaceuticals
In 2012, Charles S. Berkman earned a total compensation of $685.2K as Vice President and General Counsel at Ligand Pharmaceuticals, a 43% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $110,081 |
|---|---|
| Option Awards | $223,118 |
| Salary | $275,202 |
| Stock Awards | $72,350 |
| Other | $4,455 |
| Total | $685,206 |
Berkman received $275.2K in salary, accounting for 40% of the total pay in 2012.
Berkman also received $110.1K in non-equity incentive plan, $223.1K in option awards, $72.4K in stock awards and $4.5K in other compensation.
Rankings
In 2012, Charles S. Berkman's compensation ranked 7,641st out of 11,487 executives tracked by ExecPay. In other words, Berkman earned more than 33.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,641 out of 11,487 | 34th |
Division Manufacturing | 2,748 out of 4,253 | 35th |
Major group Chemicals And Allied Products | 718 out of 1,203 | 40th |
Industry group Drugs | 506 out of 925 | 45th |
Industry Pharmaceutical Preparations | 397 out of 700 | 43rd |
Source: SEC filing on March 12, 2015.
Berkman's colleagues
We found four more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2012.